- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07705217
The Role of Gut and Skin Microbiota in Alopecia Areata (RGSM-AA-ICS)
10 juli 2026 uppdaterad av: Tea Rosovic, Polyclinic GrandMed
The goal of this clinical trial is to learn if fecal microbiota transplantation (FMT) works to treat alopecia areata in adults. It will also learn about the safety of FMT. The main questions it aims to answer are:
- Can FMT cause hair regrowth?
- Can FMT modulate immune response? Researchers will compare FMT to a placebo (a look-alike substance that contains no drug) to see if FMT works to treat alopecia areata.
Participants will:
- Take FMT or a placebo for three consecutive days
- Follow-up evaluations will be performed at weeks 12, 24, and 48, with repeat clinical scoring, photodocumentation, microbiome analyses, laboratory testing, and quality-of-life assessment.
Studieöversikt
Status
Har inte rekryterat ännu
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
30
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Tea Rosovic, Dermatovenerology specialist
- Telefonnummer: +00385913737237
- E-post: tearosovic@gmail.com
Studieorter
-
-
-
Opatija, Kroatien
- Polyclinic GrandMed
-
Kontakt:
- Tea Rosovic, Dermatovenerology specialist
- Telefonnummer: +00385913737237
- E-post: tearosovic@gmail.com
-
Huvudutredare:
- Tea Rosovic, Dermatovenerology specialist
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Adults aged 18-65 diagnosed with Alopecia Areata (patchy or extensive) up to 10 years
- Willingness to adhere to study protocols, including FMT administration via capsules or colonoscopy.
- Ability to sign informed consent.
- SALT score≥ 20
Exclusion Criteria:
- History of gastrointestinal disorders (e.g., IBD, celiac disease).
- Recent use of antibiotics, probiotics, or prebiotics (within 2 months).
- Pregnant or breastfeeding women of childbearing potential who are unwilling or unable to use an acceptable method of birth control.
- Individuals with immunocompromised or immunosuppressed states (e.g., HIV, cancer).
- Prior FMT treatment for any condition.
- Therapy with new antidepressants or had a change in antidepressant dose within previous 3 months
- Serious medical comorbidities(including neurological or phychiatric comorbidities)
- Elevated C-reactive protein concentration, abnormal baseline laboratory tests
- Severe(anaphylactic) food allergy
- Concomitant treatments for AA: topical KS 1 week prior to randomization, topical JAK inhibitor, diphenylcyclopropenone, or other topical immunotherapies within 4 weeks prior to randomization;systemic corticosterids, immunosuppressant, intra-lesional or intra-articular corticosteroid injections, or oral JAK inhibitor within 8 weeks prior to randomization;monoclonal antibody <5 half-lives prior to randomization; probenecid at the time of randomization. Bimatoprost ophtalmic solution was allowed if on stable dose for 8 weeks.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: FMT group
Interventional group
|
Patients with alopecia areata will recieve FMT or in the 3 capsules for three consecutive days or FMT via colonoscopy
Andra namn:
|
|
Placebo-jämförare: Placebo group
This group will recieve placebo capsules or saline via colonoscopy
|
Patients will recieve three capsules with inert material or saline via colonoscopy
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Changes in hair growth- Severity of Alopecia Tool
Tidsram: From enrollment to the end of treatment at 48 weeks
|
The primary success will be a statistically significant difference in hair regrowth between the Fecal Microbiota transplantation (FMT) group and placebo group at weeks 24 and 48, assessed as a binary endpoint (regrowth yes/no) and supported by changes in SALT (Severity of Alopecia Tool) score as a standardized measurement used to quantify scalp hair loss in patients with alopecia areata.
The scale ranges from 0 (no hair loss) to 100 (complete scalp hair loss).
A clinically meaningful reduction in SALT score (≥50% improvement from baseline) will be considered a strong indicator of therapeutic efficacy.
|
From enrollment to the end of treatment at 48 weeks
|
|
Changes in hair growth- Alopecia Areata Investigator Global Assessment
Tidsram: From enrollment to the end of treatment at 48 weeks
|
The primary success will be a statistically significant difference in hair regrowth between the Fecal Microbiota transplantation (FMT) group and placebo group at weeks 24 and 48, assessed as a binary endpoint (regrowth yes/no) and supported by changes in Alopecia Areata Investigator Global Assessment (AA-IGA) to measure five clinically meaningful gradations of alopecia areata scalp-hair loss that reflects patients' and clinicians' perspectives and expectations of treatment success in alopecia areata treatment studies.
The AA-IGA score is based on the patient's SALT score.
The scale is numbered from 0, which corresponds to 0% of hair loss (ie, SALT 0), indicating no hair loss, to 4, which corresponds to 95-100% of hair loss (ie, SALT 95-100), indicating very severe hair loss.
|
From enrollment to the end of treatment at 48 weeks
|
|
Changes in hair growth- The Alopecia Areata Scale
Tidsram: From enrollment to the end of treatment at 48 weeks
|
The primary success will be a statistically significant difference in hair regrowth between the Fecal Microbiota transplantation (FMT) group and placebo group at weeks 24 and 48, assessed as a binary endpoint (regrowth yes/no) and supported by changes in The Alopecia Areata Scale (AASc) in wich primary criterion is Severity of scalp hair loss: mild 20% or less, moderate 21-49%, severe 50-100% scalp hair loss.
Secondary criteria: is any is present, increase severity rating by one level: noticeable involvement of eyebrows or eyelashes; inadequate response after at least 6 months of treatment; negative impact on psychosocial functioning resulting from AA; diffuse (multifocal) positive hait pull test consistent with pidly progressive alopecia areata.
|
From enrollment to the end of treatment at 48 weeks
|
|
Fecal microbiota transplantation modulation of the gut and skin microbiota
Tidsram: From enrollment to the end of treatment at 48 weeks
|
The primary objective of this proposal is to test the hypothesis that fecal microbiota transplantation (FMT) induces beneficial modulation of the gut and skin microbiota, leading to immunoregulatory effects in patients with alopecia areata (AA).
Characterize baseline skin, and colonic mucosal microbiota composition in patients with AA using 16S rRNA sequencing of skin and colon musosa biopsy specimens and assess changes following FMT.
|
From enrollment to the end of treatment at 48 weeks
|
|
Change in T cell subsets from Baseline to 48 weeks
Tidsram: From enrollment to the end of treatment at 48 weeks
|
Before and after Fecal microbiota transplantation patient will be taken 60-80 ml of peripheral blood for:
|
From enrollment to the end of treatment at 48 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 oktober 2026
Primärt slutförande (Beräknad)
1 februari 2027
Avslutad studie (Beräknad)
1 oktober 2027
Studieregistreringsdatum
Först inskickad
26 juni 2026
Först inskickad som uppfyllde QC-kriterierna
10 juli 2026
Första postat (Faktisk)
15 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
15 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
10 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TD25725
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
IPD used in the results publication
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .